610 related articles for article (PubMed ID: 32232482)
1. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
Ruppert AS; Dixon JG; Salles G; Wall A; Cunningham D; Poeschel V; Haioun C; Tilly H; Ghesquieres H; Ziepert M; Flament J; Flowers C; Shi Q; Schmitz N
Blood; 2020 Jun; 135(23):2041-2048. PubMed ID: 32232482
[TBL] [Abstract][Full Text] [Related]
2. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184
[No Abstract] [Full Text] [Related]
3. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
[TBL] [Abstract][Full Text] [Related]
4. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
[TBL] [Abstract][Full Text] [Related]
5. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
Bishton MJ; Hughes S; Richardson F; James E; Bessell E; Sovani V; Ganatra R; Haynes AP; McMillan AK; Fox CP
Br J Haematol; 2016 Jan; 172(2):246-54. PubMed ID: 26577576
[TBL] [Abstract][Full Text] [Related]
6. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
Yang Y; Wang L; Ma Y; Han T; Huang M
Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
8. Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.
Go SI; Kim HG; Kang MH; Park S; Lee GW
BMC Cancer; 2020 May; 20(1):439. PubMed ID: 32423395
[TBL] [Abstract][Full Text] [Related]
9. Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
Marcheselli R; Bari A; Tadmor T; Marcheselli L; Cox MC; Papotti R; Ferrari A; Baldini L; Gobbi P; Levy I; Pugliese G; Federico M; Polliack A; Pozzi S; Sacchi S
Hematol Oncol; 2020 Oct; 38(4):439-445. PubMed ID: 32495944
[TBL] [Abstract][Full Text] [Related]
10. External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Warnnissorn N; Kanitsap N; Niparuck P; Boonsakan P; Kulalert P; Limvorapitak W; Bhoopat L; Saengboon S; Chantrathammachart P; Puavilai T; Chuncharunee S
Hematology; 2022 Dec; 27(1):1237-1245. PubMed ID: 36413354
[TBL] [Abstract][Full Text] [Related]
11. Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era.
Lu CS; Chen JH; Huang TC; Wu YY; Chang PY; Dai MS; Chen YC; Ho CL
Leuk Lymphoma; 2015 Jul; 56(7):2047-55. PubMed ID: 25382616
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
[TBL] [Abstract][Full Text] [Related]
13. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
14. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).
Advani RH; Chen H; Habermann TM; Morrison VA; Weller EA; Fisher RI; Peterson BA; Gascoyne RD; Horning SJ; ; ;
Br J Haematol; 2010 Oct; 151(2):143-51. PubMed ID: 20735398
[TBL] [Abstract][Full Text] [Related]
15. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma].
Liu W; Wang X; Zhang C; Xie Y; Lin N; Tu M; Ping L; Ying Z; Deng L; Huang H; Wu M; Sun Y; Du T; Leng X; Ding N; Zheng W; Song Y; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):269-72. PubMed ID: 27093984
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of additional two cycles of rituximab administration for patients with diffuse large B-cell lymphoma in first remission].
Zhong HJ; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):756-761. PubMed ID: 27719717
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
[TBL] [Abstract][Full Text] [Related]
19. Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
Salas MQ; Mercadal S; Domingo Domenech E; Oliveira AC; Encuentra M; Climent F; Andrade Campos M; Aguilera C; Fernández de Sevilla A; Sureda A; González-Barca E
Leuk Lymphoma; 2020 Mar; 61(3):575-581. PubMed ID: 31684781
[TBL] [Abstract][Full Text] [Related]
20. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
